advanced non-squamous non-small cell lung cancer
Conditions
Brief summary
Progression free survival (PFS) at 6 months as determined by independent reviewer.
Detailed description
PFS at 6 months as determined by investigator assessment, Objective response rate (ORR), Overall survival, PFS, Incidence, nature, and severity of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0), Clinically significant changes in symptoms, function, and HRQoL scales from the patient-completed European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30 LC13); overall health status will also be assessed using the EQ-5D-5L including visual analogue scale (VAS).
Interventions
Sponsors
Intergroupe Francophone de Cancerologie Thoracique
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival (PFS) at 6 months as determined by independent reviewer. | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS at 6 months as determined by investigator assessment, Objective response rate (ORR), Overall survival, PFS, Incidence, nature, and severity of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0), Clinically significant changes in symptoms, function, and HRQoL scales from the patient-completed European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30 LC13); overall health status will also be assessed using the EQ-5D-5L including visual analogue scale (VAS). | — |
Countries
France
Outcome results
None listed